



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 600/2900

JAN 06 2003

RECEIVED

26-1
Ye
1-21

In re Application of:

Wolfgang HEIL et al.

Examiner: L.S. CHANNAVAJALA

Serial No.: 09/757,688

Group Art Unit: 1615

Filed: January 11, 2001

Title: DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY

REPLY

Assistant Commissioner for Patents
Washington, D.C. 20231

I hereby certify that this correspondence is being deposited
with the U.S. Postal Services as First Class Mail in an envelope
addressed To: Assistant Commissioner of Patents and Trademarks,
Washington, D.C. 20231 On: December 26, 2002
Name: John A. Sepp
Signature: [Signature]
Date: December 26, 2002

Sir:

In response to the Office Action mailed June 26, 2002, and in view of the Interview
conducted December 18, 2002, kindly amend the above-identified application as follows.

IN THE SPECIFICATION

Amend the paragraph at page 4, lines 21-23, to read as follows:

F2 Apart from the active substances themselves, it is envisaged that an ester or prodrug of
drospirenone may be employed in the present composition, e.g., an oxyiminopregnane
carbolactone as disclosed in WO 98/24801.

Amend the paragraph at page 9, lines 17-21, to read as follows:

F2 In preferred embodiments, the dose of DRSP corresponds to 15 to 70 mg per cycle, such as 20 to
60 mg per cycle, particularly 40 to 60 mg per cycle. The length of the cycle, as stated *supra* may